Results 91 to 100 of about 1,466,333 (379)
Detection of CD33 expression on monocyte surface is influenced by phagocytosis and temperature [PDF]
, 2019 CD33 is a myeloid-associated marker and belongs to the sialic acid-binding immunoglobulin (Ig)-like lectin (Siglec) family. Such types of receptors are highly expressed in acute myeloid leukemia, which could be used in its treatment.
Baisaeng, Nuttakorn +7 more
core +1 more source
Advanced Science, EarlyView.This review compares clinical outcomes, translational progress, and global funding trends across cancer phototherapies—photodynamic, photothermal, and photoimmunotherapy—and conventional immunotherapy. It highlights differences in treatment efficacy, clinical trial status, financial investment, and regulatory challenges, providing a comprehensive ...
Deepak S. Chauhan +6 more
wiley +1 more source
An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy
Advanced Science, EarlyView.This study develops a dimeric T cell receptor engager protein specific for tumor KRAS‐G12V mutation. The engager proteins are capable of mediating the formation of synapse between T cell and tumor cell and demonstrate substantial tumor suppression efficacy.
Keke Ma +14 more
wiley +1 more source
Nature Communications, 2022 Bispecific antibodies can have advantages compared to antibody cocktails. Here, the authors engineer and characterize two different approaches for generating bispecific SARS-CoV-2 specific antibodies and find that only one design increases antigen ...
Zhiqiang Ku +24 more
doaj +1 more source
A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A. [PDF]
, 2018 The standard of treatment for botulism, equine antitoxin, is a foreign protein with associated safety issues and a short serum half-life which excludes its use as a prophylactic antitoxin and makes it a less-than-optimal therapeutic.
Brown, Jennifer L +14 more
core +2 more sources
Cancer Discovery, 2021 The clinical benefit of PD-1 blockade can be improved by combination with CTLA-4 inhibition but is commensurate with significant irAEs sub-optimally limiting the doses of anti-CTLA-4 mAb that can be used.
S. Dovedi +34 more
semanticscholar +1 more source
Advanced Science, EarlyView.Y332D, a bispecific antibody that simultaneously blockades VEGF and TGF‐β, counteracted negative RT effects that are attributed to the upregulation of TGF‐β and VEGF, as well as further enhanced the immunostimulatory effects of RT, thereby reprograming the TME from immune “cold” to inflamed state and forming an effective in‐situ vaccine that eradicate ...
Lijuan Lyu +13 more
wiley +1 more source
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
Frontiers in Immunology, 2022 Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically revolutionized the therapeutic strategy against advanced malignancies, inspiring the exploration of various types of therapeutic antibodies.
Jing Wei +3 more
doaj +1 more source
Molecular Cancer Therapeutics, 2020 Small molecule inhibitors targeting mutant EGFR are standard of care in non–small cell lung cancer (NSCLC), but acquired resistance invariably develops through mutations in EGFR or through activation of compensatory pathways such as cMet.
S. Vijayaraghavan +12 more
semanticscholar +1 more source
Advanced Science, EarlyView.A structure‐guided peptide derived from a non‐canonical amino acid library simultaneously targets MCL‐1 and BCL‐xL to overcome apoptotic resistance in acute myeloid leukemia. Fused with a CXCR4‐binding motif, the engineered peptide exhibits selective intracellular delivery and potent in vivo efficacy, offering a promising therapeutic strategy against ...
Zhe Wang +11 more
wiley +1 more source